VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting programs from research to early discovery to clinical development. Its proprietary technology ...

UC101 is the world’s first FDA IND-approved umbilical cord blood-derived allogeneic CAR-T therapy. T cells derived from umbilical cord blood possess the natural advantages of low immunogenicity and ...

VectorBuilder made an agreement with MaxCyte, a biotechnology and electroporation company. The partnership will focus on ...

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11 to 15 in ...

CHICAGO--(BUSINESS WIRE)--GSL Biotech and VectorBuilder have formed a partnership to create a complete cloning solution, allowing customers to order their entire custom plasmids directly from ...

VectorBuilder Biotechnology has secured investor backing for its push to support gene delivery, raising a 410 million Chinese yuan ($57 million) series C financing round to upgrade and expand its R&D ...

Expansion strengthens VectorBuilder’s ability to deliver tailored and timely gene delivery solutions for North American customers while advancing its R&D and innovation capabilities. VectorBuilder, a ...

VectorBuilder Inc. – a global leader in gene delivery technologies – announced that its R&D and manufacturing center in Guangzhou won championship in the 7th “Chuangke Innovation and Entrepreneurship ...

Chicago-based VectorBuilder will drop $500 million over the next four years in a two-phase project to build a new gene therapy manufacturing facility and research institute in Guangzhou, China. The ...

CHICAGO, April 30, 2026--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology ...

VectorBuilder Inc. – a global leader in gene delivery technologies – recently announced the completion of $57 million funding, which was co-led by Legend Capital. The fund will support the ...

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China. VectorBuilder, a global gene delivery solutions company, ...